We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
Read MoreHide Full Article
Eli Lilly and Company’s (LLY - Free Report) animal health subsidiary Elanco, announced that it has closed the previously stated acquisition of German drugmaker Boehringer Ingelheim’s Vetmedica U.S. pet vaccines unit along with a fully integrated manufacturing and R&D site for $885 million.
Lilly’s’ share price gained 9.3% in the past one month compared with Zacks classified Large-Cap Pharmaceuticals industry’s fall of 2.8%.
Coming to the latest news, the acquisition of the Vetmedica portfolio of feline, canine and rabies vaccines, as well as several pipeline products, would be a strategic fit for Lilly’s animal health business that makes parasiticides, pain and dermatology medicines for food animals and companion animals.
The deal will diversify Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats. Joining Elanco's US portfolio, which includes parasiticides, pain, and dermatology medicines, will be eight product lines, namely, routine vaccines for bordetella, Lyme disease, rabies, and parvovirus. Elanco will now be able to address and provide a variety of solutions to some of the most common issues of pets. Notably, Lilly bought the animal-health division of Novartis (NVS - Free Report) in early 2015, which strengthened the Elanco division of the company. The acquisition was subject to the closing of Boehringer Ingelheim's asset swap transaction with Sanofi (SNY - Free Report) . Recently, Sanofi announced the closing of the deal under which it exchanged its Merial animal health business with the Boehringer Ingelheim’s consumer healthcare segment. This transaction was signed in Jun 2016.
Zacks Rank & Key Pick
Lilly currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Cambrex Corporation sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 23.5% in the past one year.
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
Eli Lilly and Company’s (LLY - Free Report) animal health subsidiary Elanco, announced that it has closed the previously stated acquisition of German drugmaker Boehringer Ingelheim’s Vetmedica U.S. pet vaccines unit along with a fully integrated manufacturing and R&D site for $885 million.
Lilly’s’ share price gained 9.3% in the past one month compared with Zacks classified Large-Cap Pharmaceuticals industry’s fall of 2.8%.
Coming to the latest news, the acquisition of the Vetmedica portfolio of feline, canine and rabies vaccines, as well as several pipeline products, would be a strategic fit for Lilly’s animal health business that makes parasiticides, pain and dermatology medicines for food animals and companion animals.
The deal will diversify Elanco's U.S. companion animal portfolio by complementing its offerings for dogs and cats. Joining Elanco's US portfolio, which includes parasiticides, pain, and dermatology medicines, will be eight product lines, namely, routine vaccines for bordetella, Lyme disease, rabies, and parvovirus. Elanco will now be able to address and provide a variety of solutions to some of the most common issues of pets. Notably, Lilly bought the animal-health division of Novartis (NVS - Free Report) in early 2015, which strengthened the Elanco division of the company. The acquisition was subject to the closing of Boehringer Ingelheim's asset swap transaction with Sanofi (SNY - Free Report) . Recently, Sanofi announced the closing of the deal under which it exchanged its Merial animal health business with the Boehringer Ingelheim’s consumer healthcare segment. This transaction was signed in Jun 2016.
Zacks Rank & Key Pick
Lilly currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Cambrex Corporation sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cambrex’s earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price is up 23.5% in the past one year.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>